21-09-2025, 09:15

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -
Globe Newswire21-09-2025, 09:15
21-09-2025, 09:15

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -
Globe Newswire21-09-2025, 09:15
7-08-2025, 21:05

Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia

Notified -
Globe Newswire7-08-2025, 21:05
31-05-2025, 08:00

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with T

Notified -
Globe Newswire31-05-2025, 08:00
31-05-2025, 08:00

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with T

Notified -
Globe Newswire31-05-2025, 08:00
16-01-2025, 22:05

Boehringer provides update on iclepertin Phase III program in schizophrenia

Notified -
Globe Newswire16-01-2025, 22:05